Pro, college, and high school athletes are seeing increasing numbers of COVID-19 infection and potential heart complications that could be career-ending. Ambulatory cardiac monitoring provider InfoBionic says simple and effective remote cardiac monitoring will save lives—and careers.
Brent James, the quality and patient safety expert, sees excess mortality from lack of care for life-threatening conditions other than COVID-19. Watch James' interview in this part one of three video series.
As MCOs contend with more federal and state-level regulations, below are a few adjustments leaders can make to ensure compliance while Medicaid enrollees increase.
A JAMA Oncology viewpoint argues that the COVID-19 pandemic presents a prime opportunity to make clinical trial design and execution more efficient.
The 2020 meeting, presented in a virtual format from its original host city of Amsterdam, The Netherlands, had lots of important science and a record number of viewers.
Plan sponsors should begin evaluation of PBM performance at least a year before the contract expires, say lawyers with expertise in PBM contracting.
Founders of Medicaid had reason to fear that a state-run program would have limited ability to address the needs of vulnerable populations, say authors of Health Affairs piece.
A study from the European Society of Cardiology answers a question about COVID-19: should patients keep taking well-known heart medications?
This week on Tuning Into the C-Suite, Managed Healthcare Executive's Senior Editor, Peter Wehrwein, spoke with Georgetown's Sabrina Corlette, JD. The two discussed the possible motivations behind health insurer announcing premium credits and discounts in recent weeks and months after their profits (net income, for not-for-profits) swelled due to the drop-off in routine healthcare utilization.
deCODE Genetics researchers find that 90% of those diagnosed with SARS-CoV-2 infection have antibodies to the virus four months later.
One study questions the effectiveness of remdesivir past day 10 while others support its expanded use.
The COVID-19 pandemic has led payers and providers to embrace electronic encrypted documents and other technology — and that has fostered greater collaboration between them.
Findings presented at the European Society of Cardiology meeting could open the door to the use of the gout drug as a treatment targeting the underlying inflammation of cardiovascular disease.
This week's FDA updates include an end to a boxed warning for a type 2 diabetes drug, an expanded emergency use authorization due to COVID-19, and another liquid biopsy.
Georgetown’s Sabrina Corlette says the 2021 rates were calculated before the recent announcements about COVID-19 premium relief in this part two of two video series.
COVID-19 may have made clinician burnout even more of problem. AI could help by streamlining workflows.
The pharma maker will initially produce 150 million of the 5-minute tests.
Georgetown’s Sabrina Corlette explains some of the motivations behind the spate of premium credits and discounts from health insurers in this part one of two series.
Whether the online giant has larger healthcare ambitions is unclear.
Kaufman Hall's Jim Blake says favorable numbers may just be "the calm before the storm."
But social distancing and face masks may mean less transmission of flu — and fewer colds.
But there are plenty of holdouts. Half of submissions are still done by phone or fax.
Integrated Benefits Institute study finds increased screenings for depression and detection of chronic conditions before symptoms present could have greatest impact on disability costs.
In this week’s episode of Tuning Into the C-Suite, Briana Contreras of MHE chatted with CEO of Interim HealthCare, Jennifer Sheets. She and Jennifer discussed how COVID-19 has impacted the demand for home care, how hospitals can partner with the operation and how new pursuits in healthcare will affect home care in the future.
SGLT2 inhibitors, GLP-1 receptor agonists also tackle cardiovascular disease, renal failure.
Senior Editor Peter Wehrwein speaks with Lou Ellen Horwitz, CEO of the Urgent Care Association, in this part two of two video series about centers that have not been paid yet for tests.
Results of an RCT of the coalition’s ‘hot spotting’ approach resulted in some reevaluation.
Biosimilars to Avastin and Herceptin are catching on.
Blue Cross and Blue Shield of Minnesota is among the health insurers giving businesses and individuals a break on premiums.
Scientists react negatively to FDA's handling of the Emergency Use Authorization for convalescent plasma in COVID-19.
